

Clinical Trial Protocol

Iranian Registry of Clinical Trials

10 Jul 2026

Evaluation of therapeutic effects of Neurosed syrup on the clinical symptoms of children with ADHD -A randomized double blind trial

Protocol summary

Study aim

Investigating the therapeutic effect of Neurosed syrup on the symptoms of attention deficit hyperactivity disorder (ADHD), investigating the possible side effects of using this drug.

Design

A double-blind, controlled, randomized, phase 3 clinical trial on 50 patients. A and B cards are used for randomization.

Settings and conduct

50 people from children with ADHD, referring to Imam Ali Clinic in Shahre-kord will be gradually included in the study using the available method. Using cards A and B, people are placed in two intervention or control groups. Neurosed syrup will be given to the intervention group and placebo to the control group. At this time, the symptoms related to ADHD disorder in these children are investigated using the Connors parent questionnaire, which is completed by the child's father or mother. After the completion of the one-month treatment period, the mentioned questionnaire is filled again by the parent. The changes in the obtained score are analyzed to check the effect of the drug. The doctor conducting the trial and the patient do not know the content of syrups A and B until the end of the study, so the study is double-blind.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Children with ADHD, their age should be 5-12 years. Exclusion criteria: Use of Barbiturates, drugs that suppress the central nervous system, and blood sugar-lowering drugs, Presence of other concurrent diseases, not cooperating.

Intervention groups

The intervention group (25 people) will receive Neurosed syrup, which contains the active ingredient, once a day for one month. The control group (25 people) consumes the placebo that does not contain the active substance once a day for one month.

Main outcome variables

Symptoms of ADHD (changes in the scores obtained from

the Connors parents' questionnaire before and after the intervention)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230718058834N1**

Registration date: **2023-11-21, 1402/08/30**

Registration timing: **prospective**

Last update: **2023-11-21, 1402/08/30**

Update count: **0**

Registration date

2023-11-21, 1402/08/30

Registrant information

Name

Maryam Torabi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 3668 1508

Email address

st-torabi@skums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2023-12-01, 1402/09/10

Expected recruitment end date

2024-01-30, 1402/11/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of therapeutic effects of Neurosed syrup on the clinical symptoms of children with ADHD -A randomized double blind trial

Public title

Effect of Neurosed syrup on ADHD

Purpose

Supportive

Inclusion/Exclusion criteria**Inclusion criteria:**

Children with ADHD The age of people should be 5-12 years

Exclusion criteria:

Use of Barbiturates, drugs that suppress the central nervous system, and blood sugar-lowering drugs
Presence of other concurrent diseases

Age

From **5 years** old to **12 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Patients will be gradually included in the study according to the available method and will be assigned to two intervention and control groups based on the random allocation method. For this purpose, we place 50 cards with the letter A on 25 of them and the letter B on the other 25 in an envelope and randomly take out one card for each patient. The word that comes out shows the group of the patient.

Blinding (investigator's opinion)

Double blinded

Blinding description

In order to blind the patients, Neurosed syrup and placebo are prepared from the same company and in the same packaging. The doctor conducting the trial and the patient do not know the content of the original syrups and placebo until the end of the study and extracting the results, so the study is double-blind.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of the School of Medicine, Shahrekord University of Medical Sciences

Street address

Headquarters of Shahrekord University of Medical Sciences, Kashani Street, Shahrekord, Chaharmahal va Bakhtiary, Iran

City

Shahr-e Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8815713471

Approval date

2023-06-10, 1402/03/20

Ethics committee reference number

IR.SKUMS.MED.REC.1402.012

Health conditions studied**1****Description of health condition studied**

Attention Deficit Hyperactivity Disorder (ADHD)

ICD-10 code

F90.0

ICD-10 code description

Attention-deficit hyperactivity disorder, predominantly inattentive type

Primary outcomes**1****Description**

ADHD score according to Conners parent questionnaire

Timepoint

Before the start of the intervention and one month after consuming Neurosed syrup

Method of measurement

Conners parent questionnaire

Secondary outcomes

empty

Intervention groups**1****Description**

Intervention group: A number of 25 children aged 5-12 years with ADHD referred to Imam Ali Shahrekord clinic,

who will use Neurosed syrup, which contains Melissa Officinalis extract and vitamins B and C, once a day for a month. This syrup is produced by Touba Faraz Pars company. Before and after the intervention, the symptoms related to ADHD disorder in these patients are examined using the Conners parents' questionnaire.

Category

Treatment - Drugs

2**Description**

Control group: A number of 25 children aged 5-12 with ADHD referring to Imam Ali Shahrekord clinic who will use placebo syrup once a day for one month. This syrup is produced by Touba Faraz Pars Company and it is not different from the original syrup in terms of appearance but it does not contain the active ingredient. Before and after the intervention, the symptoms related to ADHD disorder in these patients are examined using the Conners parents' questionnaire.

Category

Placebo

Recruitment centers**1****Recruitment center****Name of recruitment center**

Emam Ali clinic

Full name of responsible person

Elham Zarean

Street address

Shariati Blvd. Emam ali Clinic

City

Shahr-e Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8815713471

Phone

+98 38 3224 2696

Email

e.zarean@skums.ac.ir

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Shahre-kord University of Medical Sciences

Full name of responsible person

Elham Reisi

Street address

Kashani street, Shahrekord, Chaharmahal va Bakhtiary, Iran

City

Shahr-e Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8813833435

Phone

+98 38 3334 9507

Email

raeisi.e@skums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Shahre-kord University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Shahre-kord University of Medical Sciences

Full name of responsible person

Maryam Torabi

Position

Student

Latest degree

A Level or less

Other areas of specialty/work

General Practitioner

Street address

Kashani Street, Shahrekord, Chaharmahal va Bakhtiary, Iran

City

Shahre-Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8816754633

Phone

038322220016

Email

torabimaryam75@gmail.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Shahre-kord University of Medical Sciences

Full name of responsible person

Elham Zarean

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Psychiatrics

Street address

Kashani Street, Shahrekord, Chaharmahal va Bakhtiary, Iran

City

Shahre-Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8816754633

Phone

+98 38 3222 0016

Email

e.zarean@skums.ac.ir

Person responsible for updating data**Contact****Name of organization / entity**

Shahre-kord University of Medical Sciences

Full name of responsible person

Maryam Torabi

Position

Student

Latest degree

A Level or less

Other areas of specialty/work

General Practitioner

Street address

Kashani Street, Shahrekord ,Chaharmahal va Bakhtiary, Iran

City

Share-Kord

Province

Chahar-Mahal-va-Bakhtiari

Postal code

8816754633

Phone

038322220016

Email

torabimaryam75@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

To share the data and documents of this research, only the information related to the main outcome will be shared. Also, files that can be published and do not violate people's privacy will be published.

When the data will become available and for how long

The access period will start 6 months after the results are published.

To whom data/document is available

Our data will only be available to researchers working in academic and scientific institutions.

Under which criteria data/document could be used

Except for personal information about people, all of our data will be shared if certain requirements are met. Our data will only be used for comparable study and peer review by other researchers. Anyone working in universities or scientific institutions who wants to do similar study or confirm the accuracy of our data can access our data.

From where data/document is obtainable

All qualified individuals can collect data by referring to the project manager in order to acquire information. Contact information is available via email at torabimaryam75@gmail.com or the contact number 00989138653570.

What processes are involved for a request to access data/document

To receive information after sending the request, the requests will be reviewed within 10 days. If the above conditions are met, the information will be sent to the provided email within 30 days at most.

Comments